問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

國立臺灣大學醫學院

Division of General Internal Medicine

更新時間：2023-09-19

梁嘉德LIANG, JA-DER
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

梁嘉德

List

31Cases

2019-12-20 - 2024-08-16

IIT

Phase II

Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)

  • Condition/Disease

    advanced hepatocellular carcinoma (HCC)

  • Test Drug

    1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)

Participate Sites
2Sites

Recruiting2Sites

2015-12-01 - 2020-04-30

Phase III

A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Test Drug

    Pexastimogene Devacirepvec (Pexa Vec)

Participate Sites
6Sites

Terminated6Sites

2011-09-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-03-01 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2014-07-01 - 2022-12-31

Phase III

A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal DoxorubicinLTLD) in Hepatocellular Carcinoma (HCC) using standardized Radiofrequency Ablation (RFA) treatment time ≥ 45 minutes for solitary lesions ≥ 3 cm to ≤ 7 cm.

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin)

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2017-05-01 - 2025-12-31

Others

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    CVC /150mg tablet

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting1Sites

Terminated1Sites

彭成元
China Medical University Hospital-Taipei

未分科

2018-05-30 - 2022-12-31

Phase II

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    ATG-008

Participate Sites
6Sites

Recruiting5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2014-03-15 - 2017-12-31

Phase II

A PHASE 2, RANDOMIZED, OPEN LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACODYNAMICS, PHARMACOKINETICS OF THE ANTI-ALK-1 MAB PF-03446962 IN COMBINATION WITH BEST SUPPORTIVE CARE VS. BEST SUPPORTIVE CARE ALONE IN ADULT PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    PF-03446962 injection

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2008-03-06 - 2014-09-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2014-03-01 - 2019-01-31

Phase III

A phase III, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

  • Condition/Disease

    hepatocellular carcinoma

  • Test Drug

    K-333

Participate Sites
17Sites

Terminated16Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB